<< Back to News

System Formulary Update
Tbo-Filgrastim (Granix) & Filgrastim-sndz (Zarxio)

Situation

The Tbo-Filgrastim (Granix) and Filgrastim-sndz (Zario) product standardizations were approved by the System Pharmacy & Therapeutics Committee in September 2022.

Background

The following medications were reviewed: Tbo-Filgrastim (Granix) and Filgrastim-sndz (Zario)

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health Care System Drug Formulary:

• Tbo-Filgrastim (Granix)
  • Use of Granix injection is restricted to patients in outpatient or clinic encounters (i.e., no inpatient use) who meet the following criteria:
    • Initiation of therapy in patients with insurance restrictions that do not cover filgrastim-aafi (Nivestym)

• Filgrastim-sndz (zarxio)
  • Use of Zarxio injection is restricted to patients in outpatient or clinic encounters (i.e., no inpatient use) who meet the following criteria:
    • Initiation of therapy in patients with insurance restrictions that do not cover filgrastim-aafi (Nivestym)

Note: Stock of these formulary products may vary at individual entities 

Formulary/Epic changes will Go-Live on Tuesday, November 15, 2022.